Your session is about to expire
← Back to Search
Tetraciane gtt + Lidocaine pledget for Age-Related Macular Degeneration
N/A
Waitlist Available
Led By Thomas G Sheidow, MD, FRCSC
Research Sponsored by Lawson Health Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up pain scores reported 15 minutes after intravitreal injection.
Awards & highlights
No Placebo-Only Group
All Individual Drugs Already Approved
Approved for 5 Other Conditions
Summary
Patients with neovascular age-related macular degeneration (AMD) scheduled to receive intravitreal (IVT) Ranibizumab injection will be randomized to receive one of three topical anesthetics: (1) tetracaine drop (gtt) + lidocaine pledget to the injection site for 10 seconds (2) tetracaine gtt alone and (3) cocaine gtt alone. A questionnaire will be conducted immediately after and 15 minutes after the injection, to assess for pain.
Eligible Conditions
- Age-Related Macular Degeneration
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ pain scores reported 15 minutes after intravitreal injection.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~pain scores reported 15 minutes after intravitreal injection.
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
To elucidate the most effective topical agent for intravitreal injections.
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
Trial Design
3Treatment groups
Active Control
Group I: Tetraciane gtt + Lidocaine pledgetActive Control1 Intervention
1 gtt Tetracaine pre-IVT injection + application Lidocaine pledget to injection site
Group II: Tetracaine gttActive Control1 Intervention
Pre-Intravitreal injection - 1 gtt Tetracaine topically
Group III: Cocaine gtt aloneActive Control1 Intervention
1 gtt pre-IVT injection
Find a Location
Who is running the clinical trial?
Lawson Health Research InstituteLead Sponsor
680 Previous Clinical Trials
421,841 Total Patients Enrolled
Thomas G Sheidow, MD, FRCSCPrincipal InvestigatorIvey Eye Institute, St. Joseph's Health Care
1 Previous Clinical Trials
169 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger